18F‐fluoro‐deoxyglucose positron emission tomography in assessment of myeloma‐related bone disease: A systematic review
暂无分享,去创建一个
Otto S Hoekstra | Ingrid I Riphagen | I. Riphagen | O. Hoekstra | J. Zijlstra | S. Zweegman | Josée M Zijlstra | Danielle van Lammeren-Venema | Josien C Regelink | Sonja Zweegman | J. Regelink | Otto S. Hoekstra | Danielle van Lammeren-Venema | Josien C. Regelink
[1] M. Yun,et al. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma , 2008, Acta radiologica.
[2] H. Döhner,et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[3] R. Fanin,et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. , 2007, Haematologica.
[4] L. Baldini,et al. The Prognostic Value of F-18 Fluorodeoxyglucose Bone Marrow Uptake in Patients With Recent Diagnosis of Multiple Myeloma: A Comparative Study With Tc-99m Sestamibi , 2010, Clinical nuclear medicine.
[5] Ludwig G Strauss,et al. Prediction of Progression-Free Survival in Patients With Multiple Myeloma Following Anthracycline-Based Chemotherapy Based on Dynamic FDG-PET , 2009, Clinical nuclear medicine.
[6] Ronald Boellaard,et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[7] B. Line,et al. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma , 2006, Skeletal Radiology.
[8] C. Nanni,et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[9] P. Conti,et al. Diagnostic utility of FDG PET in multiple myeloma , 2002, Skeletal Radiology.
[10] P. Bossuyt,et al. Development and validation of methods for assessing the quality of diagnostic accuracy studies. , 2004, Health technology assessment.
[11] G. Hung,et al. Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma. , 2005, Anticancer research.
[12] L. Mileshkin,et al. A comparison of fluorine‐18 fluoro‐deoxyglucose PET and technetium‐99m sestamibi in assessing patients with multiple myeloma , 2004, European journal of haematology.
[13] M. Yun,et al. Efficacy of Multidetector Row Computed Tomography of the Spine in Patients With Multiple Myeloma: Comparison With Magnetic Resonance Imaging and Fluorodeoxyglucose-Positron Emission Tomography , 2007, Journal of computer assisted tomography.
[14] H. Schirrmeister,et al. Positron emission tomography (PET) for staging of solitary plasmacytoma. , 2003, Cancer biotherapy & radiopharmaceuticals.
[15] Lotty Hooft,et al. How to perform a comprehensive search for FDG-PET literature , 2000, European Journal of Nuclear Medicine.
[16] A. Waxman,et al. Whole-body (18)F-FDG PET identifies high-risk myeloma. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] P. Moreau,et al. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma , 2008, Haematologica.
[18] M. M. Mac Manus,et al. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. , 2009, International journal of radiation oncology, biology, physics.
[19] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.
[20] E Terpos,et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma , 2009, Leukemia.
[21] W. Oyen,et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[22] T. Buchler,et al. Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary plasmocytoma and monoclonal gammapathy of unknown significance. , 2007, Neoplasma.
[23] S S Gambhir,et al. PET in oncology: will it replace the other modalities? , 1997, Seminars in nuclear medicine.
[24] M. Salvatore,et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma , 2008, Journal of Nuclear Medicine.
[25] Gary Caputo,et al. Value of FDG PET in the assessment of patients with multiple myeloma. , 2005, AJR. American journal of roentgenology.
[26] B. Barlogie,et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. , 2009, Blood.
[27] M. Černý,et al. Synthesis of 2-deoxy-2-fluoro-D-glucose , 1969 .
[28] S. Eustace,et al. Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. , 2009, AJR. American journal of roentgenology.